COPD Clinical Trials in Orlando, FL

14 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype	Phase 3	Sanofi	<1 mi
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)	Phase 3	GlaxoSmithKline	<1 mi
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype	Phase 3	Sanofi	<1 mi
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema	N/A	Pulmonx Corporation	<1 mi
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease	Phase 3	AstraZeneca	<1 mi
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3	N/A	Apreo Health, Inc.	<1 mi
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)	Phase 3	AstraZeneca	<1 mi
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation	Phase 3	GlaxoSmithKline	<1 mi
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening	—	Freenome Holdings Inc.	5 mi
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease	Phase 2	AstraZeneca	5 mi
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)	Phase 3	AstraZeneca	5 mi
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease	Phase 2/3	Pfizer	5 mi
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment	Phase 2	Expedition Therapeutics, Inc	9 mi
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home	N/A	Temple University	16 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.